Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06717412

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Retinopathy of Prematurity (ROP) Congenital, Hereditary, and Neonatal Diseases and Abnormalities Eye Diseases Infant, Newborn, Diseases Infant, Premature, Diseases Retinal Diseases Retinopathy of Prematurity

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age
  • Bilateral type 1 ROP with one of the following retinal findings in each eye
  • Zone I, stage 1+, 2+, 3+/- disease, or
  • Zone II, stage 2+, 3+, disease, or
  • A-ROP

Exclusion criteria

  • Preterm infants with stage 4 or 5 ROP in one or both eyes
  • Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy
  • Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)
  • Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer
  • Have active ocular infection within 5 days before or on the day of first investigational treatment
  • Have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes
  • Have any contraindication for intravitreal injection clearly stated in the instructions
  • Have any ocular structural abnormality that may affect efficacy assessments
  • Have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function
  • Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments

Treatment and study plan

Conbercept

Drug

Administered as an intravitreal injection

Primary outcomes

  1. Percentage of participants with absence of active ROP and absence of unfavorable structural outcomes in both eyes during the observational period after starting study treatment

    Time frame: Week 24

    To achieve this outcome, participants cannot fulfill any of the following criteria:

    • Require intervention for ROP in either eye at or before the week 24 assessment visit with a treatment modality other than Conbercept
    • Have active ROP in either eye at the week 24 assessment visit
    • Have unfavorable structural outcomes (e.g., retinal detachment, retinal traction, macular abnormalities) in either eye at or before week 24 assessment visit

Secondary outcomes

  1. Percentage of participants with effective single intravitreal injection treatment

    Time frame: Week 24

    Effective single intravitreal injection treatment is defined as regression of ridge and plus disease after the first study treatment.

  2. Percentage of participants having reactivation at or before week 24

    Time frame: Week 24

    Reactivation of ROP is defined as ridge-like change or fibrovascular proliferation occur at the original lesion site, accompanied by the reappearance of plus disease.

  3. Percentage of participants with complete vascularization of the peripheral retina at or before week 24

    Time frame: Week 24

    Complete vascularization is defined as participants fulfill any of the following criteria:

    • Fundus photography shows the temporal vessels are less than 2 disc diameter from the ora serrata or the nasal vessels are less than 1 disc diameter from the ora serrata
    • Fluorescein fundus angiography shows the ratio of the distance from the center of the disk to the border of the vascularized zone (DB) and the distance from the center of the disk to the center of the fovea (DF) is greater than 4.0 temporally or greater than 3.3 nasally

  4. Percentage of participants requiring repeated intervention at or before week 24

    Time frame: Week 24

    Repeated intervention is defined as receiving other intervention after the first treatment, regardless of the modality.

  5. Percentage of participants requiring interventions with a second modality for ROP at or before week 24

    Time frame: Week 24

    Second modality is defined as laser photocoagulation, episcleral buckling, vitrectomy, and anti-VEGF therapy with different type of drug from the first treatment.

Other outcomes

  1. VEGF levels in the systemic circulation

    Time frame: Before the first treatment (Day 0), Day 1, Week 1 and Week 24

    Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first treatment, at Day 1, at Week 1 and Week 24.

Study contacts

Contact information is provided by the study sponsor or research team.

Wang

CONTACT

[email protected]

02984771794

Sponsors and collaborators

Lead sponsor

Wang Yusheng

Other

Registry information

Official study title

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Dec 5, 2024
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.